12 West Capital Management LP Holds Position in Alnylam Pharmaceuticals (ALNY); Medtronic (MDT) Stake Held by Union Bankshares Corp

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Union Bankshares Corp increased its stake in Medtronic Inc. (MDT) by 14.48% based on its latest 2019Q2 regulatory filing with the SEC. Union Bankshares Corp bought 4,722 shares as the company’s stock rose 15.43% . The institutional investor held 37,336 shares of the electromedical & electrotherapeutic apparatus company at the end of 2019Q2, valued at $3.64M, up from 32,614 at the end of the previous reported quarter. Union Bankshares Corp who had been investing in Medtronic Inc. for a number of months, seems to be bullish on the $144.30 billion market cap company. The stock increased 1.52% or $1.63 during the last trading session, reaching $108.56. About 3.34 million shares traded. Medtronic plc (NYSE:MDT) has risen 14.44% since October 5, 2018 and is uptrending. It has outperformed by 14.44% the S&P500. Some Historical MDT News: 16/05/2018 - Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease; 29/03/2018 - Medtronic’s newest spinal cord stimulator, Intellis, was approved in the U.S. last year; 11/04/2018 - Medtronic Presenting at Conference Apr 11; 10/04/2018 - Medtronic Expands Visualase(TM) MRI-Guided Laser Ablation System to European Markets with CE Mark Approval; 23/04/2018 - Medtronic : New Indication Expands DCB Treatment for Patients With SFA Lesions Up to 360mm; 10/04/2018 - Medtronic Presenting at Conference Tomorrow; 26/04/2018 - Two-Year Feasibility Study Results Encouraging with Medtronic Harmony(TM) Transcatheter Pulmonary Valve; 10/03/2018 - MEDTRONIC: COREVALVE TAVR SYSTEM SHOWED STRONG L-T PERFORMANCE; 24/05/2018 - MEDTRONIC 4Q ADJ EPS $1.42, EST. $1.38; 24/05/2018 - Medtronic 4Q Diabetes Rev $645M, Up 26%

12 West Capital Management Lp increased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 179.47% based on its latest 2019Q2 regulatory filing with the SEC. 12 West Capital Management Lp bought 472,000 shares as the company’s stock declined 6.55% . The hedge fund held 735,000 shares of the health care company at the end of 2019Q2, valued at $53.33 million, up from 263,000 at the end of the previous reported quarter. 12 West Capital Management Lp who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be bullish on the $8.46B market cap company. The stock increased 0.42% or $0.32 during the last trading session, reaching $77.02. About 452,776 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 19.85% since October 5, 2018 and is downtrending. It has underperformed by 19.85% the S&P500. Some Historical ALNY News: 03/04/2018 - ALNYLAM PHARMA - WILL BE REQUIRED TO PROVIDE INITIAL PAYMENT TO COVER RAW MATERIAL PURCHASES AND RESERVE APPROPRIATE RESOURCES UNDER AGREEMENT; 13/03/2018 - Alnylam Unveils Resources to `Bridge the Gap’ in Knowledge of Hereditary ATTR (hATTR) Amyloidosis Among Families at Risk; 20/04/2018 - DICERNA PHARMACEUTICALS - SETTLEMENT ALLOWS CO TO ADVANCE ALL KEY, PLANNED PIPELINE PROGRAMS; 24/04/2018 - Alnylam Pharmaceuticals: Patisiran Reduced Composite Rate of All-Cause Hospitalization and Mortality by About 50%, Relative to Placebo; 20/04/2018 - ALNYLAM PHARMACEUTICALS - ALL OTHER SETTLEMENT TERMS ARE CONFIDENTIAL; 15/05/2018 - ALNYLAM PHARMACEUTICALS INC SAYS ON MAY 12, CO’S BOARD EXPANDED SIZE OF BOARD FROM TEN TO ELEVEN - SEC FILING; 03/05/2018 - ALNYLAM 1Q ADJ LOSS/SHR $1.22; 14/03/2018 - Alnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on; 21/03/2018 - REGENERON & ALNYLAM: PACT TO DISCOVER NEW TREATMENTS FOR NASH; 26/03/2018 - ALNYLAM PHARMACEUTICALS INC - COMPANY INTENDS TO ADVANCE LUMASIRAN TO A PHASE 3 STUDY IN LATE 2018

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam Pharmaceuticals EPS beats by $0.33, beats on revenue - Seeking Alpha” on August 06, 2019, also Fool.com with their article: “3 Biotech Stocks That Could Soar This Week - Motley Fool” published on September 09, 2019, Nasdaq.com published: “5 biotech IPOs are pricing tonight with 2 more on the calendar - Nasdaq” on October 02, 2019. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Alnylam’s Partnership With Regeneron Is More Than Meets The Eye - Seeking Alpha” published on April 16, 2019 as well as Finance.Yahoo.com‘s news article titled: “Alnylam’s (ALNY) Q2 Earnings and Revenues Miss Estimates - Yahoo Finance” with publication date: August 07, 2019.

Investors sentiment increased to 1.96 in Q2 2019. Its up 0.69, from 1.27 in 2019Q1. It increased, as 20 investors sold ALNY shares while 47 reduced holdings. 36 funds opened positions while 95 raised stakes. 100.15 million shares or 7.28% more from 93.35 million shares in 2019Q1 were reported. Stevens Mgmt LP holds 14,571 shares. M&T National Bank owns 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 4,676 shares. Meeder Asset Mgmt accumulated 0.01% or 1,343 shares. Alabama-based Stanley has invested 0.05% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Sei Investments owns 75,869 shares. Sector Gamma As holds 71,900 shares or 0.84% of its portfolio. Hall Laurie J Trustee stated it has 0.14% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Blackrock Inc reported 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Prudential Incorporated reported 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). State Bank Of Montreal Can stated it has 58,654 shares or 0% of all its holdings. Dimensional Fund Advsrs Limited Partnership reported 251,258 shares. Employees Retirement Association Of Colorado reported 13,797 shares stake. Baillie Gifford And reported 6.21 million shares. Mackenzie Financial invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Delaware-based Brandywine Managers Limited Liability Com has invested 0.08% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Investors sentiment decreased to 1.14 in Q2 2019. Its down 0.30, from 1.44 in 2019Q1. It turned negative, as 57 investors sold MDT shares while 422 reduced holdings. 127 funds opened positions while 417 raised stakes. 1.04 billion shares or 1.39% more from 1.02 billion shares in 2019Q1 were reported. 7,164 are held by Boyd Watterson Asset Management Ltd Liability Corp Oh. Stack Financial Management accumulated 1.04% or 95,432 shares. Federated Invsts Pa reported 0.06% stake. Consolidated Investment Limited Company invested in 1.1% or 21,600 shares. Syntal Capital Ptnrs Ltd Liability Com holds 0.06% of its portfolio in Medtronic plc (NYSE:MDT) for 2,913 shares. Piedmont Investment Advsrs reported 0.42% of its portfolio in Medtronic plc (NYSE:MDT). Van Hulzen Asset Mngmt Ltd Liability Company owns 70,175 shares or 1.49% of their US portfolio. Donaldson Mngmt Limited Liability Company invested 2.31% in Medtronic plc (NYSE:MDT). Ipswich Management Inc has invested 0.12% in Medtronic plc (NYSE:MDT). Cullen Capital Mgmt Lc owns 14,610 shares for 0.06% of their portfolio. Lipe & Dalton reported 1% of its portfolio in Medtronic plc (NYSE:MDT). State Of New Jersey Common Pension Fund D owns 0.31% invested in Medtronic plc (NYSE:MDT) for 860,000 shares. Private Tru Na accumulated 11,161 shares or 0.22% of the stock. Amer State Bank stated it has 1.76% of its portfolio in Medtronic plc (NYSE:MDT). Gemmer Asset Mgmt Ltd Liability Corp reported 404 shares.

Medtronic plc (NYSE:MDT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.